Patient characteristics for anti-CTLA4 and anti-PD1 cohorts
Anti-PD1 | Anti-CTLA4 | |
---|---|---|
Patient characteristics | N (%) | N (%) |
Age, years | ||
<40 | 2 (5.3) | 3 (7.1) |
40–55 | 11 (28.9) | 14 (33.3) |
56–70 | 14 (36.8) | 18 (42.9) |
>70 | 11 (28.9) | 7 (16.7) |
Gender | ||
Male | 27 (71.1) | 23 (54.8) |
Female | 11 (28.9) | 19 (45.2) |
PFS | ||
<3 months | 9 (23.7) | 13 (59.1) |
3–9 months | 11 (28.9) | 6 (27.3) |
>9 months | 18 (47.4) | 3 (13.6) |
RECIST1.1 at ∼12 weeks | ||
CR | 1 (2.6) | 2 (4.8) |
PR | 11 (28.9) | 10 (23.8) |
SD | 12 (31.6) | 3 (7.1) |
PD | 14 (36.8) | 27 (64.3) |
BRAF mutation status | ||
Wild-type | 27 (73.0) | |
Mutated | 10 (27.0) | |
NRAS mutation status | ||
Wild-type | 21 (60.0) | |
Mutated | 14 (40.0) | |
Previous treatments | ||
Chemotherapy | 3 (7.9) | |
Targeted therapy | 2 (5.3) | |
Immunotherapy (ipilimumab) | 28 (73.7) | |
Radiotherapy | 4 (10.5) | |
Interferon | 1 (2.6) | |
Lactate dehydrogenase (LDH/ULN) | ||
<1 | 20 (54.1) | 27 (67.5) |
≥1 | 17 (45.9) | 13 (32.5) |
S100 | ||
<0.2 μg/L | 10 (27.8) | |
≥0.2 μg/L | 26 (72.2) | |
ANC | ||
<8 g/L | 35 (92.1) | 40 (95.2) |
≥8 g/L | 3 (7.9) | 2 (4.8) |
ALC | ||
<1.5 g/L | 25 (65.8) | 28 (66.7) |
≥1.5 g/L | 13 (34.2) | 14 (33.3) |
Leukocytes | ||
<9.6 g/L | 34 (89.5) | |
≥9.6 g/L | 4 (10.5) | |
Basophils | ||
<0.15 g/L | 20 (52.6) | |
≥0.15 g/L | 18 (47.4) | |
Eosinophils | ||
<0.7 g/L | 36 (94.7) | |
≥0.7 g/L | 2 (5.3) |
NOTE: N, number of patients in each category. %, representation in percent for each category.